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OBJECTIVE:
 
 To examine the impact of carvedilol on the
utilization and cost of inpatient care in patients with
chronic heart failure. METHODS: A health-economic
evaluation of carvedilol was undertaken in conjunction
with the US Carvedilol Heart Failure Trials Program, in
which 1094 patients with NYHA Class II–IV heart fail-
ure were randomized to treatment with carvedilol or pla-
cebo (696 and 398 respectively) as an adjunct to conven-
tional therapy (digitalis, diuretics, ACE inhibitors). Patients
were treated for up to 15 months (mean  6.5 months).
Measures of interest included the numbers of hospitaliza-
tions, days spent in special-care units and in hospital
overall, the utilization of selected cardiovascular proce-
dures, and the cost of cardiovascular-related inpatient
care. Resource utilization data were collected for all hos-
pitalizations occurring between randomization and the
end of follow-up. Costs were estimated based on ob-
served levels of resource use and secondary data sources.
RESULTS: The mean number of heart failure admissions
was 53% lower among patients randomized to carvedilol
(0.07 vs 0.15 for placebo [P  0.03]); comparable reduc-
tions for cardiovascular and all-cause admissions were
30% (0.21 vs 0.30 [P  0.02]) and 25% (0.30 vs 0.40
[P  0.003]) respectively. For heart failure admissions,
mean length of stay and the mean number of ICU/CCU
days were reduced by 37% (6.8 vs 10.8 days [P  0.03])
and 83% (0.7 vs 4.3 [P  0.001]) respectively; for car-
diovascular admissions, comparable reductions were 32%
(7.4 vs 10.8 days [P  0.30]) and 73% (1.5 vs 5.6 [P 
0.05]) respectively. Utilization of selected cardiovascular
procedures was also nominally lower among patients re-
ceiving carvedilol. Estimated costs of inpatient care for
heart failure and cardiovascular admissions were 81% (P 
0.02) and 57% (P  0.02) lower respectively among
carvedilol patients. CONCLUSION: In chronic heart
failure patients receiving conventional therapy, addition
of carvedilol reduced inpatient resource utilization and
costs over the period of study.
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OBJECTIVES:
 
 We developed a generic decision analyti-
cal model to predict health and economic outcomes of
different management options for cytomegalovirus (CMV)
infection and disease in bone marrow and solid organ
transplant patients. METHODS: The model considers
the most prevalent management strategies, thereby em-
phasizing the important difference between “infection”
and “disease”: 1. prophylaxis and testing for infection,
followed by pre-emption in case of infection; 2. only
testing for infection followed by pre-emption in case of
infection; and 3. wait, and treat once disease occurs.
Clinical data was obtained from randomised controlled
studies. A Bayesian analysis was applied to distinguish ef-
fectiveness of current management options for CMV in-
fection versus CMV disease, an aspect that is currently
underreported in literature. For each of the three strate-
gies and in each transplant type, different management
options and resource use data was obtained from key ex-
perts in large transplant centres in France, Germany, and
the UK. Unit cost data was obtained from official sources
from the health care payer’s perspective. Time horizon
was one year. RESULTS: The model produces results for
a variety of scenarios and management options. In gen-
eral, prophylaxis is cost-effective in BMT (16,000 Euro/
LYG; SE  6,900) and dominant in liver transplants
compared to alternative strategies, while in renal trans-
plants, test and pre-empt is more preferable. Some partic-
ular current strategies such as acyclovir IV prophylaxis in
bone marrow and IV immune globulin prophylaxis in re-
nal transplants are not supported by the results. Sensitiv-
ity analyses show at the same time the robustness of cur-
rent conclusions and the potential options for disease
management. CONCLUSIONS: This model provides an
exhaustive description of management options for CMV
in transplant patients, and is useful both in current deci-
sion-making for optimal disease management, as well as
in the assessment of future targets for research.
 
ID2
 
COST-EFFECTIVENESS ANALYSIS OF 
HEXAVALENT MENINGOCOCCAL B
OUTER-MEMBRANE-VESICLE VACCINE
 
Bos JM
 
1
 
, Rümke HC
 
2
 
, Welte R
 
3
 
, Postma MJ
 
1
 
, Jager JC
 
3
 
1
 
Groningen University Institute for Drug Exploration/
Groningen Research Institute of Pharmacy (GUIDE/GRIP), 
Groningen, The Netherlands; 
 
2
 
Laboratory of Clinical Vaccine 
Research, National Institute of Public Health and the 
Environment, Bilthoven, The Netherlands; 
 
3
 
Department of 
Health Services Research, National Institute of Public Health 
and the Environment, Bilthoven, The Netherlands
OBJECTIVE: To estimate the cost-effectiveness and pro-
gram costs of vaccination with hexavalent meningococcal
B outer-membrane-vesicle (OMV) vaccine within the
framework of the Dutch vaccination program for new-
borns. METHODS: A pharmacoeconomic decision-anal-
ysis model was applied, linking epidemiological and eco-
nomic data. Epidemiological data were obtained from
